as of 12-10-2025 3:37pm EST
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 57.8M | IPO Year: | 2018 |
| Target Price: | $1.00 | AVG Volume (30 days): | 458.0K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $2.35 | Next Earning Date: | 11-13-2025 |
| Revenue: | $4,392,000 | Revenue Growth: | -90.43% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Sr. Vice President and COO
Avg Cost/Share
$0.97
Shares
8,098
Total Value
$7,696.10
Owned After
135,146
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | EQ | Sr. Vice President and COO | Nov 25, 2025 | Sell | $0.97 | 8,098 | $7,696.10 | 135,146 |
See how EQ stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EQ Equillium Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.